Content about Paul Bisaro

December 21, 2012
Watson to present at Goldman Sachs, J.P. Morgan healthcare conferences

Watson Pharmaceuticals will present at two conferences sponsored by financial banks, the company said.

November 1, 2012
Watson to change brand in 2013

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

October 31, 2012
Watson sells Rugby OTC business to Harvard Drug Group for $117 million

Watson Pharmaceuticals on Wednesday announced the sale of its Rugby over-the-counter business to the Harvard Drug Group — a distributor and provider of private-label OTCs and generic prescription products under the Major Pharmaceuticals brand — for approximately $117 million.

May 16, 2012
ReportersNotebook — Chain Pharmacy, 5/21/12

Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.

May 10, 2012
New office to help integrate Actavis into Watson

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

March 21, 2011
GPhA responds to potential OGD funding cuts; announces exit of Gordon Johnston

The generic drug industry’s main lobby in Washington is hoping to head off cuts to the Food and Drug Administration’s Office of Generic Drugs, which it said could have a “devastating impact” on those who rely on generics.

March 9, 2011
Watson promotes two SVPs

Generic drug maker Watson Pharmaceuticals has promoted two executives to EVP, the company said Wednesday.

February 22, 2011
GPhA announces executive committee, board of directors

The Generic Pharmaceutical Association has elected its 2011 executive committee and board of directors, the generic drug industry trade group announced. As part of a reorganization last year, the board has been reduced to 12 members.

© 2013 Drug Store News. All Rights Reserved.